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ABSTRACT:
We investigated genetic polymorphisms in the pregnane X recep-
tor (NR1I2) in Korean individuals (n  83) and the effects of NR1I2
genotypes on rifampin-mediated induction of bupropion hydroxy-
lation. The pharmacokinetics of bupropion and hydroxybupropion
were evaluated after an oral dose of bupropion (150 mg) adminis-
tered before and after rifampin treatment for 7 days in 35 healthy
subjects. The area under the time-concentration curve (AUC) ratio
of hydroxybupropion to bupropion in CYP2B6*6 carriers was sig-
nificantly lower than that in CYP2B6*6 noncarriers in both the basal
and rifampin-induced states (p  0.012). Among the CYP2B6*6
carriers (n  13), the NR1I2 TGT (25385T  g.7635G  g.8055T)
carriers exhibited a significantly lower AUC ratio, representing the
CYP2B6 hydroxylation activity, compared with the TGT noncarri-
ers, in the induced state (11.9 versus 20.3, p  0.045). The percent
difference in the AUC ratio between the basal and induced states
was also significantly different (212% versus 58.8%, p  0.006).
However, no significant difference was observed among the NR1I2
TGT genotypes for the CYP2B6*6 noncarriers (n  22). In conclu-
sion, it is suggested the NR1I2 TGT genotype decreases the bu-
propion hydroxylation induced by treatment with rifampin, partic-
ularly in CYP2B6*6 carriers.
Introduction
The pregnane X receptor (PXR), also known as the steroid and
xenobiotic receptor or pregnane-activated receptor, is an orphan nu-
clear receptor family member and is encoded by the nuclear receptor
subfamily 1 (NR1I2) gene (Bertilsson et al., 1998; Blumberg et al.,
1998; Lehmann et al., 1998). After ligand binding, PXR forms a
heterodimer with the retinoid X receptor (NR1B), which then binds to
PXR response elements located in the 5-flanking regions of PXR
target genes, resulting in transcriptional activation (Rosenfeld et al.,
2003). PXR is a master transcriptional regulator of many important
genes involved in xenobiotic metabolism and transport, including
genes encoding cytochromes P450 (e.g., CYP3A4, CYP3A5, CYP2B6,
CYP2C19, and CYP2C8) and transporters [e.g., MDR1 (ABCB1),
MRP2 (ABCC2), and OATP2 (SLCO1B1)] (Lamba et al., 2005).
Genetic polymorphisms in NR1I2 may explain the interindividual
variability of PXR activity, which affects the disposition and interaction
of various drugs via an induction mechanism. Most previous studies have
reported that variant alleles of NR1I2 are associated with decreased rifampin-
mediated CYP3A4 induction (Hustert et al., 2001; Koyano et al., 2004; Lim
et al., 2005; Wang et al., 2007), but increased transcriptional activation of
PXR was observed at single nucleotide polymorphisms (SNPs) of
25385CT, 24113GA, g.7635AG, or g.8055CT (Zhang et al.,
2001). However, the clinical consequences of these polymorphisms have not
been consistently validated, and clinically important variation has not yet
been demonstrated by well controlled clinical pharmacogenetic studies.
CYP2B6 plays a primary role in the metabolism of therapeutic
drugs such as cyclophosphamide, bupropion, and efavirenz (Chang et
al., 1993; Kirchheiner et al., 2003; Ward et al., 2003). CYP2B6
comprises less than 1% of the total liver microsomal cytochrome P450
content and is expressed in various extrahepatic tissues, including the
brain (Shimada et al., 1994). The CYP2B6 enzyme is highly poly-
morphic, and its genetic polymorphisms have been discovered (Lang
et al., 2001). The common allele CYP2B6*6 (c.516GT and
c.785AG) leads to aberrant splicing of pre-mRNA, resulting in
reduced expression of functional transcript and protein in human liver
(Hofmann et al., 2008). Associations between CYP2B6 genetic poly-
morphisms and pharmacokinetics have been reported for bupropion
(Kirchheiner et al., 2003), thiotepa (Ekhart et al., 2009), and efavirenz
(Rotger et al., 2007).
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Bupropion, an atypical antidepressant and smoking cessation aid,
was reportedly used as a selective marker of CYP2B6 activity in
previous studies (Faucette et al., 2000). A representative PXR agonist,
rifampin, has been shown to induce CYP2B6 activity as evidenced by
significantly increased bupropion hydroxylation after rifampin treat-
ment (Loboz et al., 2006). In that study, subjects with CYP2B6*6/*6
or CYP2B6*1/*6 exhibited decreased bupropion clearance relative to
that of subjects with CYP2B6*1/*1 after rifampin treatment, whereas
clearance in the absence of rifampin treatment was similar (Loboz et
al., 2006). On the basis of this preliminary result, rifampin-induced
CYP2B6 activity was suggested to be associated with both the exis-
tence of the CYP2B6*6 allele and certain other factors such as genetic
polymorphism of PXR.
Both CYP2B6 and NR1I2 polymorphisms may be associated with
the clinical pharmacokinetics and/or drug-drug interactions of bupro-
pion; however, there have been no clinical pharmacogenetic studies of
CYP2B6 substrates in the rifampin-induced state in relation to the
PXR variants. Therefore, we investigated the genetic polymorphisms
in PXR and examined the relationship between these genetic poly-
morphisms and metabolic induction of bupropion by rifampin admin-
istration in humans.
Materials and Methods
Subjects. Thirty-five unrelated Korean subjects participated in a clinical
pharmacokinetics (PK) study of bupropion. All subjects were healthy, as
determined by medical history, physical examination, vital signs, 12-lead
ECG, drug screening, and routine clinical laboratory tests performed within 3
weeks of the start of the study. Regular heavy drinkers, smokers of more than
10 cigarettes/day, and those with a body weight differing by more than 20%
from their ideal weight were excluded.
To survey NR1I2 genetic polymorphisms in the Korean population, a total
of 83 individual samples from subjects who had donated blood, including the
patients in this PK study, were genotyped. CYP2B6 genotypes were divided
into CYP2B6*6 carrier and noncarrier groups using methods described previ-
ously (Jinno et al., 2003; Hofmann et al., 2008). This study was approved by
the Institutional Review Board of Seoul National University Hospital, Seoul,
Korea. All procedures were performed in accordance with the recommenda-
tions of the Declaration of Helsinki on biomedical research involving human
subjects and with the International Conference on the Harmonization of
Technical Requirements for the Registration of Pharmaceuticals for Human
Use–Good Clinical Practice guidelines. Written informed consent for partici-
pation in the study and genotyping was obtained from all subjects before
enrollment.
Study Design. The subjects were admitted to the clinical research ward of
the Clinical Trials Center on the night before bupropion administration. After
an overnight fast, subjects were given a single dose of 150 mg of bupropion
(Wellbutrin SR tablet; GlaxoSmithKline Korea, Seoul, Korea) with 240 ml of
water at 9:00 AM on day 1. Subjects fasted for 4 h after drug administration,
except for drinking water 2 h after dosing. Venous blood samples for PK
analysis (8 ml) were collected using an intravenous catheter before dosing and
0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 9, 12, 24, 30, and 36 h after dosing. Alcohol, soft
drinks, smoking, drugs, and caffeine-containing beverages were prohibited
during the study. After 7 days of washout, subjects were given 600 mg of
rifampin (Rifodex tablet; ChongKunDang Pharmaceutical Corp., Seoul, Ko-
rea) every morning, on an outpatient basis, on days 8 to 14. On day 15, after
overnight fasting, subjects were given 150 mg of bupropion in the same
manner as described for day 1.
Genotyping. NR1I2. Genomic DNA was extracted from peripheral whole
blood using a QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden,
Germany). Genotyping was done using TaqMan allelic discrimination assays
on an AB 7500 Real-Time PCR System (Applied Biosystems, Foster City,
CA). Ten microliters of PCR mixture were prepared with 5 l of 2 TaqMan
Genotyping Master Mix, 0.5 l of 20 Drug Metabolism Genotyping Assay
Mix, 3.5 l of DNase-free water, and 1 l of genomic DNA. Genotyping
for NR1I2 25385CT (rs3814055, assay no. C_27504984_30), NR1I2
24113GA (rs2276706, assay no.: C_15882316_10), NR1I2 g.7635AG
(rs6785049, assay no.: C_29280426_10), and NR1I2 g.8055CT (rs2276707,
assay no.: C_15882324_10). Detection of SNPs was performed with validated
TaqMan genotyping assays purchased from Applied Biosystems. The PCRs
were as follows: initial denaturation at 95°C for 10 min, followed by 50 cycles
of denaturation at 92°C for 15 s and annealing/extension at 60°C for 1 min.
The allelic discrimination results were determined after amplification by
performing an endpoint read. AB Sequence Detection System (SDS) 7500
software (version 1.4; Applied Biosystems) was used for the analysis.
DNA direct sequencing. To identify NR1I2 24020[GAGAAG]()
(rs3842689) sequencing was applied. The PCR method was used to amplify
one NR1I2 fragment with University of California Santa Cruz In-Silico PCR
(http://genome.ucsc.edu/cgi-bin/hgPcr?command start). The final volume of
the PCR was 10 l, consisting of 10 ng of DNA, 0.5 M concentrations of
each primer pair, 0.25 mM dNTPs, 3 mM MgCl2, 1 l of 1 reaction buffer,
and 0.25 U Taq DNA polymerase (Intron Biotechnology, Seongnam-si, Gyeo-
nggi-do, Korea). The PCR products were purified and sequenced using a
BigDye Terminator Cycle Sequencing kit and an ABI 3730xl automated
sequencer (Applied Biosystems). The sequencing primers were the same as
those used for the PCR amplification. Mutation analyses were performed using
Phred, Phrap, Consed, and PolyPhred 5.04 software (http://droog.mbt.
washington.edu/PolyPhred.html).
CYP2B6. Genomic DNA was prepared from peripheral blood samples using
the nucleic acid isolation device QuickGene-Mini80 (Fujifilm, Tokyo, Japan).
To determine the presence of CYP2B6*4 (c.785AG only) and CYP2B6*6
(c.516GT and c.785AG), DNA proximal to two polymorphic sites,
c.785AG (rs2279343) and c.516GT (rs3745274), was amplified by PCR,
followed by SNaPShot analysis according to the manufacturer’s instructions
(ABI PRISM SNaPShot Multiplex kit). The sequences of forward and reverse
primers and probes were 5-CTTTCTTGCAGCTGTTTG-3, 5-CCTCTGTCTT-
TCATTCTGTC-3, and 5-GGTAGGTGTCGATGAGGTCC-3 for c.785AG
and 5-CGTGACGTGCTGGTACA-3, 5-CTCCATGTCCCTGATTCTT-3,
and 5-AGATGATGTTGGCGGTAATGGA-3 for c.516GT, respectively. The
validity of the method was confirmed by sequencing.
Drug Concentration Analysis. The plasma concentrations of bupropion
and hydroxybupropion were determined by high-performance liquid chroma-
tography with ultraviolet detection using a modification of a previously de-
scribed method (Jennison et al., 1995). Standards of bupropion and hydroxy-
bupropion were purchased from BD Gentest (Woburn, MA), and trazodone as
an internal standard was obtained from Sigma-Aldrich (St. Louis, MO). One
milliliter of plasma was extracted with 10 ml of n-heptane-isoamyl alcohol
(1000:15, v/v) including 25 g of trazodone as an internal standard after the
addition of 150 l of 0.1 M hydrochloride. The organic phase was evaporated,
reconstituted with 100 l of the mobile phase, and injected into a high-
performance liquid chromatography system (Gilson, Villiers-le-Bil, France). A
mobile phase of 50 mM KH2PO4-acetonitile (810:190, v/v, pH 2.5) was used
at a flow rate of 1.0 ml/min through a Capcell Pak C18 column (150 4.6-mm
i.d., 5.0-mm particle size; Shiseido, Tokyo, Japan). The ultraviolet detector
was set to monitor 214 nm. The lower limit of quantification for bupropion and
hydroxybupropion was 2 and 10 ng/ml, respectively, and the calibration curves
for bupropion and hydroxybupropion were linear from the lower limit of
quantification to 1000 ng/ml (correlation coefficient 0.997). The accuracy
was 91.9 to 106.1% for bupropion and 100.6 to 111.5% for hydroxybupropion,
whereas the interbatch coefficients of variation were 7.7 and 9.2% for
bupropion and hydroxybupropion, respectively.
Pharmacokinetics and Statistical Analysis. PK parameters were calcu-
lated using the actual sampling times. Maximum plasma drug concentrations
(Cmax) were determined from the observed values. Plasma concentrations for
the terminal phase were fitted to a log-linear line using the least-squares
method to obtain the terminal half-life (t1/2). Areas under the time-concentra-
tion curve for bupropion (AUC_bup) and hydroxybupropion (AUC_hyd) were
calculated using a combination of the trapezoidal rule from 0 to 36 h.
AUC_hyd was divided by AUC_bup for each period, representing the activity
of metabolite formation of bupropion to hydroxybupropion (formation clear-
ance divided by metabolite clearance). Percent differences in the PK param-
eters between the basal and rifampin-induced states were used to assess the
induction effect of rifampin treatment and were calculated as 100  (in-
duced  basal)/basal. WinNonlin (version 5.2; Pharsight, Mountain View,
CA) was used for the PK analysis.
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Considering the small and uneven number of subjects, comparisons of
parameters between the two groups was conducted nonparametrically using the
Wilcoxon rank-sum test. Comparisons of parameters between the metabolic
induced state and the basal state for each subject were conducted using a paired
t test. Multiple linear regression analysis was applied to evaluate the signifi-
cance of effects due to genotype, gender, and body weight and their contribu-
tions to the total observed variability. p  0.05 was considered statistically
significant. Linkage disequilibrium and haplotype assembly analysis were
performed using the Haploview 4.1 program (Broad Institute of Harvard and
MIT, Cambridge, MA), on the basis of a standard expectation maximization
algorithm, to reconstruct individual haplotypes from the population genotype
data.
Results
Genetic Polymorphisms of NR1I2 in the Korean Popula-
tion. The frequencies of the NR1I2 alleles 25385C, 24113G,
24020[GAGAAG], g.7635A, and g.8055C in the 83 samples were 0.681,
0.681, 0.681, 0.518, and 0.590, respectively. The distribution of the geno-
types was consistent with Hardy-Weinberg equilibrium (p 0.05, 2 test).
NR1I2 25385CT, 24113GA, and 24020[GAGAAG]() dis-
played 100% linkage (r2 1.0), and a significant linkage (r2 0.746) was
found between g.7635AG and g.8055CT. SNPs in positions 25385,
g.7635, and g.8055 resulted in six haplotypes: CAC, CGT, TGT, TAC, CGC,
and TGC, with population frequencies of 0.428, 0.211, 0.199, 0.090, 0.042,
and 0.030, respectively. The CAC haplotype was the most common and was
regarded as the wild-type allele, and the CGT and TGT haplotypes were the
primary variant alleles, based on their allele frequencies. Considering that the
25385CT SNP has been reported previously to exhibit altered transcrip-
tional activity (Zhang et al., 2001; Wang et al., 2009), the subjects were
divided into TGT carrier (n 13) and noncarrier (n 22) groups, based on
the existence of the NR1I2 TGT haplotype, as well as the25385CT SNP.
Results of the Clinical Study. The demographic characteristics of
the subjects and the distributions of the CYP2B6 genotypes were not
significantly different among the NR1I2 haplotypes (Table 1). After
rifampin treatment, AUC_bup markedly decreased and AUC_hyd/
AUC_bup, which represents the metabolic activity of bupropion into
hydroxybupropion, significantly increased (p  0.001, paired t test).
The percent differences were significantly greater in the NR1I2 TGT
noncarriers (228%) than in the TGT carriers (169%) (p  0.018).
AUC_hyd in the TGT noncarriers did not differ between the basal and
induced states (0.43%, p 0.464), whereas in the TGT carriers it was
significantly decreased in the induced state (24.8%, p 0.0002). As
a result, there were significant differences among the NR1I2 geno-
types in terms of the percent difference in AUC_hyd between the
basal and induced states (p  0.001). These findings are consistent
with the results grouped by the 25385TT genotypes (Table 2).
However, there was no significant difference in AUC_bup, AUC_hyd,
or their ratios between the NR1I2 TGT carriers and noncarriers or
between the 25385CC and CT groups in either the basal or induced
metabolic states (Table 2).
The effects of the CYP2B6 and NR1I2 genotypes were considered
together and are shown by subgroup in Table 3. The CYP2B6*6
carriers had significantly lower AUC_hyd and AUC_hyd/AUC_bup
compared with the CYP2B6*6 noncarriers in both the basal and
induced states. The percent differences in AUC_hyd after rifampin
treatment were significantly different among the NR1I2 genotypes,
regardless of the CYP2B6 genotype.
There were no significant differences found in AUC_hyd/
AUC_bup among the NR1I2 TGT genotypes for the CYP2B6*6
noncarriers. In contrast, for the CYP2B6*6 carriers, the NR1I2 TGT
carriers had a significantly lower AUC_hyd/AUC_bup than the TGT
noncarriers in the induced state (11.9 versus 20.3, p  0.045), and the
percent difference after rifampin induction was significantly different
(212% versus 58.8%, p  0.006) (Table 3). Individual plots of
AUC_hyd/AUC_bup by CYP2B6 and NR1I2 genotypes for each
period indicate much lower increases for the NR1I2 TGT 
CYP2B6*6 carriers (Fig. 1).
The concentration-time profiles for bupropion were similar regard-
less of genotype for both metabolic states. However, the profiles for
hydroxybupropion were different for the CYP2B6*6  NR1I2 TGT
carriers than for the other groups, with lower values in the basal state
and much lower values in the induced state (Fig. 2). The Cmax values
of bupropion and hydroxybupropion in the basal and induced states
were not significantly different between the NR1I2 TGT carriers and
noncarriers (data not shown). In the basal state, the hydroxybupropion
TABLE 1
Demographic data and CYP2B6 genotypes in the subjects of the NR1I2 TGT
haplotype groups
TGT Noncarrier
(n  22) TGT Carrier (n  13) p
No. of subjects
Male 16 5 0.0751a
Female 6 8
Age (yr) 22.7  1.6 23.2  2.3 0.9715b
Weight (kg) 65.0  10.1 59.5  11.5 0.0941b
CYP2B6 genotype (n)
*1/*1 (19)  *1/*4 (3) 13 9 0.6638a
*1/*6 (11)  *6/*6 (2) 9 4
a Fisher’s exact test.
b Wilcoxon rank-sum test between the two groups.
TABLE 2
Effects of NR1I2 genotypes on the rifampin-mediated metabolic induction of bupropion hydroxylation
TGT Noncarrier (n  22) TGT Carrier (n  13) pa 25385CC (n  17) 25385CT (n  17) 25385TT (n  1) pb
AUC_bup (ng  h/ml)
Basal 1274  324 1194  315 0.585 1260  350 1247  294 929 0.5525
Induced 435  196 406  176 0.785 418.2  212.5 432.6  168.1 370 0.8505
%differencec 66.7  10.4* 65.1  15.8* 0.960 67.8  11.2* 64.8  14.1* 60.2 0.607
AUC_hyd (ng  h/ml)
Basal 9343  3118 11,558  4568 0.204 9290  3276 10,695  4112 16,053 0.231
Induced 9003  2435 8541  3304 0.489 8840  2413 8837  3202 8577 0.941
%difference 0.43  23.3 24.8  11.8* <0.001 0.78  20.2 14.8  23.2* 46.6 0.017
AUC_hyd/AUC_bup
Basal 7.7  3.1 10.3  4.6 0.088 7.8  3.4 9.0  3.9 17.3 0.195
Induced 26.0  19.2 27.3  17.0 0.759 27.9  21.5 25.3  15.3 23.2 0.978
%difference 228  95* 169  176* 0.018 232  98.3* 182  153* 34.2 0.035
* p  0.01, paired t test between the basal and induced states.
a Wilcoxon rank-sum test for the NR1I2 groups.
b Kruskal-Wallis test for 25385CT groups; p  0.05 indicated in bold.
c %difference represents the percent difference between basal and induced state, calculated as 100  (induced  basal)/basal.
94 CHUNG ET AL.
Cmax for the TGT carriers (499.2  190.9 ng/ml) was slightly higher
than that for the TGT noncarriers (382.9  134.3 ng/ml, p  0.088).
Multiple linear regression analysis of the percent difference of
AUC_hyd/AUC_bup, including the demographic and genetic factors,
showed that only the NR1I2 TGT haplotype had a significant effect
(p  0.0049) and explained 22.2% (r2  0.222) of the total variabil-
ity. The r2 value increased to 0.356 when the model included body
weight, the CYP2B6 genotype, or gender variables (partial r2 0.061,
0.048, and 0.025, respectively).
Discussion
We investigated genetic polymorphisms in NR1I2 in the Korean
population. Allele frequencies of 25385CT and 24020 6-base
pair deletion were similar to those in other ethnic groups and frequen-
cies of g.7685AG and g.8055CT were slightly higher than those
of Caucasian and African-American populations. Strong linkage
among the 25385, 24113, and 24020 SNPs was identified, as
reported previously (Zhang et al., 2001; Uno et al., 2003; Lamba et al.,
2005; Wang et al., 2007).
We found that the percent differences in AUC_hyd and AUC_hyd/
AUC_bup after rifampin treatment were significantly different be-
tween the NR1I2 TGT carriers and noncarriers. These differences
were highly significant in the CYP2B6*6 carriers, with the lowest
value observed in the NR1I2 TGT carrier group (58%, the percent
increase of the AUC_hyd/AUC_bup). However, significant differ-
ences were not observed among the CYP2B6*6 noncarriers. These
findings support the hypothesis that the increased metabolism of
bupropion with rifampin treatment is affected by both NR1I2 and
CYP2B6 genetic polymorphisms. Specifically, it can be postulated
that reduced metabolic capacity is more pronounced in individuals
with both the CYP2B6*6 and reduced function PXR alleles.
Because Zhang et al. (2001) reported that several variant NR1I2
genotypes exhibited increased induction activity after rifampin treat-
ment, various studies have suggested certain effects of PXR variants,
despite inconsistent results. Higher mRNA levels of intestinal
CYP3A4 were associated with g.7635G and g.8055T, and greater
induction of CYP3A activity was found in25385TT subjects than in
25385CC subjects, as measured by an erythromycin breath test
(Zhang et al., 2001). In addition, a recent report showed that the
NR1I2 haplotype, including TGT, was associated with weaker basal
activity but greater inducible transcriptional activity of CYP3A4,
based on a PK study of nifedipine (Wang et al., 2009). However,
these studies were performed with CYP3A4 substrates, a very
small sample size (n  3), and limited in vivo PK information
regarding the substrate drugs, and, in addition, their associated
mechanism has not been experimentally demonstrated. Consistent
with our findings, most studies have suggested that the same PXR
genetic variants exhibited reduced PXR transcriptional activity. A
6-base pair (bp) deletion in intron 1a (24020), which was linked
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FIG. 1. Individual subject profiles showing AUC_hyd/AUC_bup ratios for the
basal and rifampin-induced states in the NR1I2 and CYP2B6 genotype groups
(n  35).
TABLE 3
Effects of the CYP2B6 genotype and NR1I2 genotypes on rifampin-mediated metabolic induction of bupropion hydroxylation
CYP2B6*6 Noncarrier (n  22)
Pa
CYP2B6*6 Carrier (n  13)
pa pb
TGT Noncarrier (n  13) TGT Carrier (n  9) TGT Noncarrier (n  9) TGT Carrier (n  4)
AUC_bup (ng  h/ml)
Basal 1307  318 1187  308 0.333 1227  347 1209  376 0.877
1257  312 1222  340 0.539
Induced 437  188 344  161 0.243 430.6  216.7 545.2  132.3 0.165
399  180 466  197 0.306
%differencec 67.2  10.8 70.8  12.2 0.512 65.8  10.4 52.3  16.8 0.199
68.7  11.3 61.7  13.7 0.649
AUC_hyd (ng  h/ml)
Basal 10,465  3112 12,796  4007 0.324 7723  2449 8776  5073 0.940
11,419  3609 8047  3269 0.004
Induced 9849  1923 9756  3050 0.845 7782  2680 5808  2117 0.199
9811  2378 7174  2609 0.013
%difference 0.22  28.0 23.3  10.5 0.021 0.76  15.8 -28.1  15.6 0.011
9.39  25.1 8.13  20.5 0.468
AUC_hyd/AUC_bup
Basal 8.6  3.5 11.3  3.8 0.066 6.5  2.0 8.0  6.2 0.758
9.7  3.8 6.9  3.6 0.012
Induced 30.0  23.5 34.1  15.5 0.333 20.3  8.9 11.9  7.7 0.045
31.7  20.3 17.7  9.2 0.012
%difference 228  107 218  192 0.262 212  78 58.8  41.9 0.006
225  143 164  99.7 0.287
p  0.05 is indicated in bold.
a Wilcoxon rank-sum test for the NR1I2 groups within each CYP2B6 genotype group.
b Wilcoxon rank-sum test for the CYP2B6 groups.
c %difference represents the percent difference between basal and induced state, calculated as 100  (induced  basal)/basal.
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completely to 25385CT and 24113GA SNPs in our study,
has been reported to be associated with a total loss of transcrip-
tional activity when expressed in the HepG2 cell line (Uno et al.,
2003). This observation is consistent with the results for one of our
subjects with 25385TT, who had the lowest percent increase
(34.2%) in AUC_hyd/AUC_bup after rifampin induction. In pa-
tients with primary sclerosing cholangitis, which is caused by
abnormal bile acid detoxification, the rs6785049 (g.7635AG)
GG group exhibited a reduced survival rate associated with de-
creased transcription activity of PXR (Karlsen et al., 2006). An-
other example of clinically decreased PXR transactivation in a
PXR variant was shown in patients with breast cancer who took
doxorubicin. PXR*1B haplotypes, which consisted of g.2654TC
and IVS6-17CT polymorphisms, were found to be associated
with significantly decreased hepatic mRNA expression of PXR and
its downstream target genes, CYP3A4 and ABCB1. The PXR*1B
haplotype was also significantly associated with reduced clearance
of doxorubicin (Sandanaraj et al., 2008).
In the basal state, the mean value of AUC_hyd/AUC_bup was
somewhat higher in the NR1I2 TGT carriers than noncarriers (more
prominently in the CYP2B6*6 noncarriers, p 0.066). The reason for
this is unknown, but this phenomenon was also reported in an in vitro
study of PXR.2 expression. PXR.2 is an alternatively spliced form of
PXR that lacks 111 nucleotides encoding 37 amino acids in the
ligand-binding domain. Basal CYP2B6 expression levels are in-
creased in untreated PXR.2 cells: however, CYP2B6 induction activ-
ity decreased after treatment with rifampin (Lin et al., 2009). Other
effects may be linked to the NR1I2 TGT haplotype and basal meta-
bolic activity of CYP2B6. For example, impaired transactivation of
PXR may initiate other induction pathways, leading to compensation
or overcompensation, depending on the circumstances.
Our results suggest that the CYP2B6*6 allele is associated with
reduced metabolic biotransformation regardless of the NR1I2 geno-
type. In vitro studies of the CYP2B6 substrates, bupropion and efa-
virenz, have demonstrated that the *6 allele expresses up to 4-fold less
protein with lower activity than the wild-type allele (Desta et al.,
2007). The molecular mechanism associated with the CYP2B6*6
allele involves aberrant splicing, leading to lower functional mRNA
and protein levels as well as reduced activity (Hofmann et al., 2008).
Bupropion is associated with several safety problems including sei-
zures (Ross and Williams, 2005) and failure to achieve smoking
cessation in certain groups, which may be due to differences in
metabolic induction. Therefore, the knowledge of a patient’s genotype
may help determine the optimal regimen for bupropion, especially
when drug interactions are considered. Moreover, the expression of
the CYP2B6 protein and mRNA is region-specific (Gervot et al.,
1999). Expression has been observed in neurons and astrocytes in the
human brain (Miksys et al., 2003), the target site of bupropion,
suggesting that the NR1I2 and CYP2B6 genotypes may be more
closely associated with clinical effects than would be suggested by the
apparent PK parameters obtained from plasma data. In addition,
transporter activity at the blood-brain barrier must be considered in
this context. Thus, the influence of NR1I2 polymorphisms on the
clinical efficacy and adverse effects of bupropion should be examined
in the future in a large-scale controlled clinical study.
The primary limitation of this study was the small number of
volunteers in the variant type groups. However, at a minimum it may
be confidently inferred that the effect of the NR1I2 genotype is small
for CYP2B6*6 noncarriers (n  22). In addition, we were not able to
examine all of the known functional polymorphisms of PXR; instead,
considering the small number of subjects, we focused on five sites that
are frequently found in Asian individuals. A potential role for other
nuclear receptors, such as the constitutive androstane receptor (CAR),
farnesoid X receptor, and glucocorticoid receptor, as well as metab-
olizing enzymes and drug transporters in bupropion disposition and
rifampin-mediated induction, may be postulated. CAR is well known
to be related to CYP2B activation (Honkakoski and Negishi, 1998). A
different mechanism of induction is evident in metamizole, which
does not act as a direct ligand for PXR or CAR but selectively
increases human hepatic CYP2B6 and CYP3A4 expression and ac-
tivity (Saussele et al., 2007). Further investigation of the in vivo
effects of CAR and other factors together with PXR and CYP2B6 in
the induction of bupropion hydroxylation is therefore needed.
In conclusion, our study suggests that the NR1I2 TGT or 25385T
haplotype may decrease the induced metabolism of bupropion after
rifampin administration in CYP2B6*6 carriers, whereas this effect was
not significant in CYP2B6*6 noncarriers. Controlled pharmacogenetic
clinical studies and large-scale pharmacodynamic genetic polymor-
phism studies in patients are both needed to clarify the role of the
NR1I2 polymorphism in the efficacy, safety, and drug interactions of
CYP2B6 substrate drugs.
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FIG. 2. Mean plasma concentration-time profiles of bupropion
(BUP) and hydroxybupropion (hydroxyBUP) after oral administra-
tion of 150 mg of bupropion in the NR1I2 and CYP2B6 genotype
groups: A, CYP2B6*6 noncarrier  NR1I2 TGT noncarrier;
B, CYP2B6*6 noncarrier  NR1I2 TGT carrier; C, CYP2B6*6
carrier  NR1I2 TGT noncarrier; and D, CYP2B6*6 carrier 
NR1I2 TGT carrier. The dashed and solid lines indicate basal and
rifampin-induced states, respectively.
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